Kiran Mazumdar-Shaw, often referred to as India's 'Queen of Biotech', established Biocon nearly five decades ago from humble beginnings in a rented garage. According to Bloomberg Markets, the company has evolved into one of the world's leading manufacturers of insulin and a major player in the biosimilars sector, generating multibillion-dollar revenues and establishing itself as a cornerstone of India's pharmaceutical industry.
As Mazumdar-Shaw navigates the transition of leadership to her successors, she has begun reflecting publicly on her journey as a female entrepreneur in India's business landscape. Her mission has consistently centered on making life-saving therapeutics accessible to patients globally, a vision that has shaped Biocon's corporate strategy and market positioning over decades.
Beyond her company's operational achievements, Mazumdar-Shaw is also engaged in broader conversations about India's competitive positioning in the technology-driven future, particularly regarding artificial intelligence adoption and regulation. Her perspective on how India can strategically prepare for emerging technologies reflects the evolving concerns of India's industrial leadership class.
